Hjem
Mari Kyllesø Halles bilde

Mari Kyllesø Halle

Forsker
  • E-postmari.halle@uib.no
  • Besøksadresse
    Kvinneklinikken
    Jonas Lies vei 72
    5053 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Jeg har en PhD fra Universitetet i Bergen (2017) der jeg undersøkte molekylære endringer i uterine svulster. Jeg er for tiden forsker i Bergen Gynekologiske Krefforskningsgruppe der mitt hovedfokus er å karakterisere kreftdrivere som man kan målrette behandling mot - med fokus på de mest aggressive uterine svulstene. jeg ser på genomiske, molekylære, radiologiske, og kliniskpatologiske drivere i disse kreftsvulstene og prøver å finne gode biomarkører for forbedret diagnostikk og prediksjon av behandlingsrespons. 

Vitenskapelig artikkel
  • Vis forfatter(e) (2024). Clinicopathological and radiological stratification within FIGO 2018 stages improves risk-prediction in cervical cancer. Gynecologic Oncology. 110-117.
  • Vis forfatter(e) (2023). Visceral fat percentage for prediction of outcome in uterine cervical cancer. Gynecologic Oncology. 62-68.
  • Vis forfatter(e) (2023). Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease. EBioMedicine. 14 sider.
  • Vis forfatter(e) (2023). MRI-based radiomic signatures for pretreatment prognostication in cervical cancer. Cancer Medicine.
  • Vis forfatter(e) (2022). What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer? Insight into Imaging. 1-14.
  • Vis forfatter(e) (2022). Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value. British Journal of Cancer. 9 sider.
  • Vis forfatter(e) (2022). Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer. European Radiology. 6444-6455.
  • Vis forfatter(e) (2022). Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. Nature Communications. 1-17.
  • Vis forfatter(e) (2022). Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer. Cancers. 1-16.
  • Vis forfatter(e) (2022). APOBEC3A/B deletion polymorphism and endometrial cancer risk. Cancer Medicine.
  • Vis forfatter(e) (2021). Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer. Biomarkers. 302-308.
  • Vis forfatter(e) (2021). High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling. International Journal of Molecular Sciences. 17 sider.
  • Vis forfatter(e) (2021). Genomic characterization and therapeutic targeting of HPV undetected cervical carcinomas. Cancers. 15 sider.
  • Vis forfatter(e) (2021). Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. NPJ GENOMIC MEDICINE.
  • Vis forfatter(e) (2021). A radiogenomics application for prognostic profiling of endometrial cancer. Communications Biology. 12 sider.
  • Vis forfatter(e) (2021). A gene signature identifying CIN3 regression and cervical cancer survival. Cancers. 1-18.
  • Vis forfatter(e) (2021). A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. British Journal of Cancer. 1690-1698.
  • Vis forfatter(e) (2020). Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology. 1-9.
  • Vis forfatter(e) (2020). High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Vis forfatter(e) (2020). Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.
  • Vis forfatter(e) (2019). PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • Vis forfatter(e) (2019). Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology. 400-406.
  • Vis forfatter(e) (2019). Blood metabolites associate with prognosis in endometrial cancer. Metabolites. 1-15.
  • Vis forfatter(e) (2018). The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients. European Journal of Hybrid Imaging. 1-14.
  • Vis forfatter(e) (2018). Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • Vis forfatter(e) (2017). Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Vis forfatter(e) (2017). PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • Vis forfatter(e) (2017). MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC Cancer. 1-6.
  • Vis forfatter(e) (2017). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Vis forfatter(e) (2017). Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology. 672-677.
  • Vis forfatter(e) (2017). Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology. 432.e1-432.e17.
  • Vis forfatter(e) (2016). Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • Vis forfatter(e) (2016). The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Vis forfatter(e) (2016). The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer. Tumour Biology. 10697-10702.
  • Vis forfatter(e) (2016). Integrative protein-based prognostic model for early-stage endometrioid endometrial cancer. Clinical Cancer Research. 513-523.
  • Vis forfatter(e) (2016). Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Vis forfatter(e) (2016). Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • Vis forfatter(e) (2015). Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Vis forfatter(e) (2015). ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • Vis forfatter(e) (2014). The evolution and functional divergence of the beta-carotene oxygenase gene family in teleost fish-Exemplified by Atlantic salmon. Gene. 268-274.
  • Vis forfatter(e) (2014). Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • Vis forfatter(e) (2014). Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • Vis forfatter(e) (2014). Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10. Cancer Research. 852-861.
  • Vis forfatter(e) (2014). Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathology, Research and Practice. 774-778.
  • Vis forfatter(e) (2014). Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer. 3003-3010.
  • Vis forfatter(e) (2014). Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • Vis forfatter(e) (2014). Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • Vis forfatter(e) (2014). High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • Vis forfatter(e) (2014). Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics. 481-497.
  • Vis forfatter(e) (2014). Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Vis forfatter(e) (2013). Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 216-223.
  • Vis forfatter(e) (2013). Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications. 12 sider.
  • Vis forfatter(e) (2013). GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics. 362-370.
  • Vis forfatter(e) (2012). High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • Vis forfatter(e) (2012). Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 980-987.
Leserinnlegg
  • Vis forfatter(e) (2012). Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology. 516-519.
Doktorgradsavhandling
  • Vis forfatter(e) (2017). Molecular alterations suggesting new treatment strategies in uterine carcinomas.
Errata
  • Vis forfatter(e) (2023). Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595] (eBioMedicine (2023) 92, (S2352396423001603), (10.1016/j.ebiom.2023.104595)). EBioMedicine.

Se fullstendig oversikt over publikasjoner i CRIStin.

Twitter